InvestorsHub Logo
Followers 14
Posts 2863
Boards Moderated 0
Alias Born 12/23/2014

Re: Jlivermore29 post# 292

Friday, 10/16/2020 12:33:42 PM

Friday, October 16, 2020 12:33:42 PM

Post# of 461
thats how i read it anyways

He reminds investors that plasma can be manufactured into an IV or subQ formulation, and subQ is the growth engine and more profitable for CS



Interestingly there was no mention of Grifol's Xembify which could offset any softness in new CSL prescriptions. In the razor/razorblade model, there are higher margins on the razorblades(tubes and needles). So earnings could be somewhat cushioned?

indication expansion, new Ig drugs, new non-Ig drugs


All of these possible some day but no time frame has been offered.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KRMD News